UNSPSC 51111775: Bizelesin

This classification denotes an antineoplastic alkylating agent with the molecular formula C43H36Cl2N8O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L0O9OBI87E, chemically known as 1,3-bis(2-(((s)-1-(chloromethyl)-1,6-dihydro-5-hydroxy-8-methylbenzo(1,2-b:4,3-b)dipyrrol-3(2h)-yl)carbonyl)indol-5-yl)urea but more generally known as bizelesin, which bears US NIH Compound Identifier 60794. European Medicines Agency schedules Bizelesin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05863MIG.

UNSPSC 51111775 Bizelesin is a Commodity code, but the recent state and local opportunities tagged under it show no purchases of bizelesin itself — a specialized chemotherapy compound. Instead, the procurement activity under this code reflects state and local health agencies and cooperative purchasing vehicles buying naloxone (opioid reversal agents), safe drug deactivation systems, medical and first aid supplies for emergency response, generic multi-source pharmaceuticals and over-the-counter products, and direct-to-manufacturer pharmacy benefit services. The issuing bodies include county health departments (Seminole County, Florida), municipal fire rescue services (City of Tampa), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances (Minnesota MMCAP). The work being solicited ranges from emergency medical consumables and pharmaceutical supply chain management to state-level pharmacy benefit program redesign.

Activity is concentrated in Florida, Texas, and Minnesota, with the MMCAP opportunity explicitly serving multiple state and local members. Recent solicitations include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries due July 26, 2023; the City of Tampa's IFB for 169 line items of medical and first aid supplies for the Fire Department Rescue Division with a $700,000 estimated contract value and a March 13, 2026 deadline, designated as a sheltered market opportunity for certified Small Local Business Enterprises with a 5 percent bid discount; MMCAP's RFP for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026 and award effective July 1, 2026; and the Texas HHS Commission's RFI for direct-to-manufacturer prescription program capabilities posted April 3, 2026. The mismatch between the code name (bizelesin) and the actual procurement activity suggests that this Commodity code is being applied inconsistently or may serve as a catch-all for specialized pharmaceutical and pharmacy-benefit acquisitions by state and local health agencies.